Clinical Trials
0
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
No trial phase data available
No trial data available
No trial data available
No approval data available
- AusperBio completed patient enrollment in its Phase III AUSHINE trial of AHB-137, enrolling over 570 HBeAg-negative chronic hepatitis B patients within five months of regulatory approval. - The antisense oligonucleotide therapy demonstrated a 30% functional cure rate in Phase IIa studies for patients with baseline HBsAg levels of 100-1,000 IU/mL at 72-week follow-up. - AHB-137 employs a triple-mechanism approach targeting HBsAg suppression, viral DNA replication inhibition, and immune reactivation to address the unmet need for functional cure in chronic hepatitis B. - The rapid enrollment reflects urgent clinical need, as approximately 254 million people worldwide live with hepatitis B virus, with 75 million chronically infected in China alone.
- Researchers have identified a stromal immunosuppressive barrier in gastric cancer composed of SPP1+ and C1QC+ macrophages along with exhausted CD8+ T cells that contributes to immune checkpoint inhibitor resistance. - The study used single-cell RNA sequencing and spatial transcriptomics to map immune cell interactions, revealing that MIF signaling from macrophages drives T cell exhaustion and immunotherapy resistance. - Based on barrier-associated features, the team developed a four-subtype classification system for gastric cancer patients that could guide personalized immunotherapy strategies and predict treatment outcomes.
